This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): rosiglitazone, rosiglitazone XR
Description: Avandia (rosiglitazone), a member of the thiazolidinedione class of antidiabeticagents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highlyselective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARg). Activation of PPARg nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPARg-responsive genes also participate in the regulation of fatty acid metabolism.
Deal Structure: On 4/32/99, SmithKline Beecham entered into an agreement with Bristol-Myers Squibb to co-promote Avandia in the United States for the treatment of type 2 diabetes.
SmithKline Beecham will solely direct and fund all continuing development of Avandia.
Partners: Bristol-Myers Squibb Company
Pink Sheet Pharmacovigilance
Additional information available to subscribers only: